• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Efficacy and safety of evogliptin in patients with type 2 diabetes and non-alcoholic fatty liver disease: A multicentre, double-blind, randomized, comparative trial.

作者信息

Han Eugene, Huh Ji Hye, Lee Eun Y, Bae Ji C, Chun Sung W, Yu Sung H, Kwak Soo H, Park Kyong S, Lee Byung-Wan

机构信息

Division of Endocrinology and Metabolism, Department of Internal Medicine, Keimyung University School of Medicine, Daegu, South Korea.

Division of Endocrinology and Metabolism, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, South Korea.

出版信息

Diabetes Obes Metab. 2022 Apr;24(4):752-756. doi: 10.1111/dom.14623. Epub 2021 Dec 27.

DOI:10.1111/dom.14623
PMID:34918436
Abstract
摘要

相似文献

1
Efficacy and safety of evogliptin in patients with type 2 diabetes and non-alcoholic fatty liver disease: A multicentre, double-blind, randomized, comparative trial.依格列净治疗2型糖尿病合并非酒精性脂肪性肝病患者的疗效与安全性：一项多中心、双盲、随机对照试验
Diabetes Obes Metab. 2022 Apr;24(4):752-756. doi: 10.1111/dom.14623. Epub 2021 Dec 27.
2
Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.新型二酰基甘油 O-酰基转移酶 2 反义抑制物治疗非酒精性脂肪性肝病：一项多中心、双盲、随机、安慰剂对照的 2 期临床试验。
Lancet Gastroenterol Hepatol. 2020 Sep;5(9):829-838. doi: 10.1016/S2468-1253(20)30186-2. Epub 2020 Jun 15.
3
Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials.非酒精性脂肪性肝病伴或不伴糖尿病患者的降糖药物疗效和安全性：一项更新的随机对照试验系统评价。
Diabetes Metab. 2020 Nov;46(6):427-441. doi: 10.1016/j.diabet.2019.12.007. Epub 2020 Jan 7.
4
Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study.达格列净和 n-3 羧酸对 2 型糖尿病患者非酒精性脂肪性肝病的影响：一项双盲随机安慰剂对照研究。
Diabetologia. 2018 Sep;61(9):1923-1934. doi: 10.1007/s00125-018-4675-2. Epub 2018 Jul 3.
5
DPP-4 Inhibitor in Type 2 Diabetes Mellitus Patient with Non-Alcoholic Fatty Liver Disease: Achieving Two Goals at Once?2型糖尿病合并非酒精性脂肪性肝病患者使用二肽基肽酶-4抑制剂：能否一举两得？
Endocrinol Metab (Seoul). 2022 Dec;37(6):858-860. doi: 10.3803/EnM.2022.605. Epub 2022 Dec 26.
6
Hepatic role in an early glucose-lowering effect by a novel dipeptidyl peptidase 4 inhibitor, evogliptin, in a rodent model of type 2 diabetes.新型二肽基肽酶4抑制剂依格列净在2型糖尿病啮齿动物模型中早期降糖作用的肝脏机制
Eur J Pharmacol. 2016 Jan 15;771:65-76. doi: 10.1016/j.ejphar.2015.11.029. Epub 2015 Nov 24.
7
Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease.钠-葡萄糖协同转运蛋白2抑制剂达格列净对2型糖尿病合并非酒精性脂肪性肝病患者血清可溶性二肽基肽酶-4水平的影响。
Int J Clin Pract. 2019 May;73(5):e13335. doi: 10.1111/ijcp.13335. Epub 2019 Apr 1.
8
Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial.培格非格司亭（BMS-986036），一种聚乙二醇化成纤维细胞生长因子 21 类似物，在非酒精性脂肪性肝炎患者中的应用：一项随机、双盲、安慰剂对照、2a 期临床试验。
Lancet. 2019 Dec 22;392(10165):2705-2717. doi: 10.1016/S0140-6736(18)31785-9. Epub 2018 Dec 13.
9
Evogliptin: First Global Approval.依格列净：全球首次获批。
Drugs. 2015 Nov;75(17):2045-9. doi: 10.1007/s40265-015-0496-5.
10
Cardiovascular safety of evogliptin in patients with type 2 diabetes: A nationwide cohort study.在 2 型糖尿病患者中，依格列净的心血管安全性：一项全国性队列研究。
Diabetes Obes Metab. 2021 Jun;23(6):1232-1241. doi: 10.1111/dom.14330. Epub 2021 Feb 10.

引用本文的文献

1
Metabolic-Dysfunction-Associated Steatotic Liver Disease: Molecular Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies.代谢功能障碍相关脂肪性肝病：分子机制、临床意义及新兴治疗策略
Int J Mol Sci. 2025 Mar 25;26(7):2959. doi: 10.3390/ijms26072959.
2
Pharmacological treatment options for metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus: A systematic review.2型糖尿病患者代谢功能障碍相关脂肪性肝病的药物治疗选择：一项系统评价
Eur J Clin Invest. 2025 Apr;55(4):e70003. doi: 10.1111/eci.70003. Epub 2025 Feb 12.
3
Comparison of the efficacy and safety of hypoglycemic treatments in patients with non-alcoholic fatty liver disease and type-2 diabetes: a systematic review and Bayesian network analysis.
非酒精性脂肪性肝病合并2型糖尿病患者降糖治疗的疗效与安全性比较：一项系统评价和贝叶斯网络分析
Eur J Clin Pharmacol. 2023 Nov;79(11):1465-1474. doi: 10.1007/s00228-023-03561-w. Epub 2023 Sep 8.
4
Evogliptin Directly Inhibits Inflammatory and Fibrotic Signaling in Isolated Liver Cells.依格列净直接抑制分离肝细胞中的炎症和纤维化信号通路。
Int J Mol Sci. 2022 Oct 1;23(19):11636. doi: 10.3390/ijms231911636.